- Global Pharma News & Resources

Global Auto injectors Treatment Market is expected to grow at a CAGR of 27.63% during the forecast period from 2018-2025

A new research report published by Fior Markets with the title Global Auto injectors Treatment Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Diabetes, Anaphylaxis and Other Therapies), Type, End User (Home Care Settings and Hospitals & Clinics), Regionâ?? and Global Forecast 2018-2025.

The global auto injectors treatment market is expected to grow from USD 27.82 Billion in 2017 to USD 172.38 Billion by 2025 at a CAGR of 27.63% during the forecast period from 2018-2025. North market is expected to witness substantial growth over the next decade. Rising in the healthcare expenditure and readiness to take up novel products for emergency care and chronic & acute diseases are the propelling the growth of auto-injectors market in this region are attributing to the growth of the market in future.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.


Key participants in the industry include Biogen Idec, Inc., Antares Pharma, Inc., Becton, Dickinson and Company, Novartis International AG, Mylan, Inc., Pfizer, Inc., Unilife Corporation, Scandinavian Health Limited (SHL) Group, Ypsomed Holdings AG, Sanofi S. A., ELI Lilly among others. Major companies are investing in R&D for technological advancements and novel products. For instance, in 2015, Bayer HealthCare launched Betaconnect, which is an electronic auto-injectors used for the treatment of relapsing-remitting multiple sclerosis (RRMS). This auto-injectors offers complete drug dosage for improved compliance and potentially reduces the overall cost. In 2016, SMC Ltd. acquired Oval Medical Technologies Ltd., for the development of next generation auto-injectors to enhance its product portfolio and to expand drug delivery capabilities. Furthermore, in 2017, Kaleo Pharmaceutical launched supplemental new drug application (sNDA) named as â?? AUVI-Q (0.1mg). This drug was reviewed on a priority basis by the U.S. Food and Drug Administration (US FDA). AUVI-Q is the first known epinephrine auto-injector. It is designed to treat an allergic reactions especially in infants.

The therapy segment is classified into rheumatoid arthritis, multiple sclerosis, anaphylaxis, cardiovascular diseases, psoriasis and migraine. Rheumatoid arthritis based segment is anticipated to grow with the highest CAGR of 29.31% in the forecast period. Increase in the incidence of anaphylactic shock, rise and governmentâ??s support for allowing the marketing of the instrument in various locations is driving the growth of the market. End user segment is divided into segments such as homecare, and hospitals. Hospital segment held the largest market share in 2017. Proper diagnosis and treatment provided at hospitals will lead to the growth of segment in future.

Growing demand for targeted drug delivery systems for treatments of chronic diseases, increasing self-medication practices and supportive government reimbursements and marketing approvals for auto-injectors are some of the factors for the growth of the market. High cost of autoinjectors and lack of practice may hamper the growth of market. However, new drug delivery systems, new formulations combined with innovation and developments in the biological drugs boosting the growth of the market in coming years.


About the report:
The global auto injectors treatment market is analyzed on the basis of value (USD Billion), volume (K Units), export (K Units), and import (K Units). All the segments have been analyzed on global, regional and country basis. The study includes an analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porter’s five forces model, attractiveness analysis, raw material analysis, and competitor position grid analysis.

Customization of the Report:
The report can be customized as per client requirements. For further queries, you can contact us on or +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

Contact Us
Mark Stone
Phone: +1-201-465-4211

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 31-Jul-2020